Author: Dr. David Lowemann

Vatican: Pope Francis Shows Slight Improvement, Resumes Some Work

Pope Francis showed slight improvement in laboratory tests Monday and resumed some work activities, including calling a parish in Gaza City that he has kept in touch with since the war there began, the Vatican said. Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for […]

Published on February 24, 2025

Coverage Inconsistent for Popular Weight-Loss Drugs

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is […]

Published on February 24, 2025

Genetic evidence that diabetes drug GLP-1 receptor agonists achieve weight loss primarily by reducing fat mass more than muscle

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms. A research team assessed the impact of […]

Published on February 24, 2025